Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTransMedics Group Inc

TransMedics Group Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
88.24 USD 0.28 ( 0.32%)
Last update at 2026-11-06T21:00:00Z
VOLUME
3948819
Market Cap
4705.42M

Momentum Score

…

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
76.50
Low
88.44
High
52 Week Price Range
36.42
Low
143.46
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
87.96
Dividend Yield
-
Revenue TTM
296.92M
Revenue Per Share
9.10
Gross Profit TTM
65.27M
Debt / Equity
3.76
ROE
-5.79%
Net Debt
121.13M
ROCE
-4.83%
Diluted EPS TTM
-0.34

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.16M -44.18M -28.72M -33.51M -23.71M
Net income -36.23M -44.22M -28.75M -33.55M -23.76M
Selling general administrative 51.69M 38.28M 24.19M 23.60M 12.31M
Selling and marketing expenses 18.21M - 0.93M - 1.02M
Gross profit 65.27M 21.16M 16.64M 13.86M 5.73M
Reconciled depreciation 3.48M 1.82M 1.58M 1.22M 0.77M
Ebit -31.44M -39.43M -26.38M -29.60M -20.45M
Ebitda -32.44M -40.30M -24.73M -28.81M -19.68M
Depreciation and amortization -1.00M -0.88M 1.65M 0.79M 0.77M
Non operating income net other - -0.88M - - -
Operating income -31.44M -39.43M -26.38M -29.60M -20.24M
Other operating expenses 124.90M 69.69M 52.02M 53.21M 33.25M
Interest expense 3.73M 3.87M 3.98M 4.35M 2.72M
Tax provision 0.07M 0.04M 0.03M 0.04M 0.04M
Net interest income -3.73M -3.87M -3.98M -4.35M -2.72M
Income tax expense 0.07M 0.04M 0.03M 0.04M 0.04M
Total revenue 93.46M 30.26M 25.64M 23.60M 13.02M
Total operating expenses 96.71M 60.59M 43.02M 43.47M 25.97M
Cost of revenue 28.19M 9.10M 9.00M 9.74M 7.28M
Total other income expense net -4.73M -4.75M -2.33M -3.90M -0.76M
Net income from continuing ops -36.23M -44.22M -28.72M -33.55M -23.76M
Net income applicable to common shares -36.23M -44.22M -28.75M -33.55M -23.76M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 706.05M 277.15M 134.89M 152.03M 105.30M
Intangible assets 2.35M - - - -
Other current assets 8.03M 2.90M 5.46M 2.33M 1.54M
Total liab 568.85M 89.77M 67.04M 48.13M 50.65M
Total stockholder equity 137.20M 187.38M 67.85M 103.89M 54.65M
Deferred long term liab - - - 1.60M -
Other current liab 38.22M 18.64M 16.34M 10.41M 8.70M
Common stock 641.11M 666.28M 510.49M 502.22M 424.13M
Capital stock 641.11M 666.28M 510.49M 502.22M 424.13M
Retained earnings -503.70M -478.68M -442.45M -398.23M -369.48M
Other liab - - - 1.60M 0.39M
Good will 11.99M - - - -
Other assets - 0.50M 0.50M 0.51M 0.51M
Cash 394.81M 201.18M 25.58M 24.58M 20.09M
Total current liabilities 54.93M 23.66M 23.24M 11.88M 16.11M
Current deferred revenue 1.96M 0.24M 0.25M 0.26M 0.17M
Net debt 121.13M -133.63M -16.98M 10.08M 14.05M
Short term debt 2.04M 1.44M 8.60M - -
Short long term debt total 515.95M 67.56M 8.60M 34.66M 34.15M
Other stockholder equity - -0.23M 68.04M -0.10M -105.30M
Property plant equipment - 24.35M 15.69M 4.75M 4.79M
Total current assets 510.65M 252.29M 118.70M 146.77M 100.00M
Net tangible assets - 187.38M 67.85M 103.89M 54.65M
Short term investments - 0.00M 66.87M 101.06M 60.60M
Net receivables 63.58M 27.61M 5.93M 6.86M 6.56M
Long term debt 506.20M 58.70M 35.20M 34.66M 34.15M
Inventory 44.23M 20.61M 14.86M 11.93M 11.22M
Accounts payable 12.72M 3.34M 6.65M 1.21M 7.25M
Accumulated other comprehensive income -0.20M -0.23M -0.19M -0.10M -0.00M
Common stock total equity - - 510.49M 502.22M 424.13M
Retained earnings total equity - - -442.45M -398.23M -
Non currrent assets other 0.06M 0.50M 0.50M 0.51M 0.51M
Non current assets total 195.39M 24.85M 16.19M 5.26M 5.30M
Capital lease obligations 9.74M 8.86M 8.60M - -
Long term debt total - - 35.20M 34.66M 34.15M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 54.51M 32.79M -41.14M -60.50M 12.72M
Change to liabilities -3.27M 9.96M -5.74M 3.31M 0.23M
Total cashflows from investing activities 54.51M 29.27M -41.60M -60.50M 12.31M
Net borrowings 22.46M 22.46M 22.46M 22.46M 24.36M
Total cash from financing activities 167.93M 1.39M 75.55M 92.72M 22.06M
Change to operating activities 6.21M 1.96M 2.11M 2.35M 0.65M
Net income -36.23M -44.22M -28.75M -33.55M -23.76M
Change in cash 175.60M 1.00M 4.49M -0.15M 8.30M
Begin period cash flow 26.08M 25.08M 20.59M 20.74M 12.44M
End period cash flow 201.68M 26.08M 25.08M 20.59M 20.74M
Total cash from operating activities -45.82M -28.86M -30.27M -32.29M -25.98M
Issuance of capital stock 139.85M 0.00M 75.67M 97.37M 0.00M
Depreciation 3.48M 1.82M 1.58M 1.22M 0.77M
Other cashflows from investing activities - - - -60.34M 12.72M
Dividends paid - - -0.36M - -
Change to inventory -8.02M -4.89M -1.74M -4.12M -2.70M
Change to account receivables -21.68M 0.84M -0.22M -3.17M -2.51M
Sale purchase of stock 0.51M 0.42M 0.36M 0.20M 0.05M
Other cashflows from financing activities 63.61M 0.97M 2.13M -4.64M 31.14M
Change to netincome 13.70M 7.81M 2.49M 1.67M 1.33M
Capital expenditures 11.91M 3.52M 0.46M 0.17M 0.42M
Change receivables - 0.84M - - -
Cash flows other operating - -1.54M - - -
Cash and cash equivalents changes - 1.80M - - -
Change in working capital -26.76M 3.00M -5.59M -1.63M -4.33M
Stock based compensation 10.32M 6.88M 2.41M 0.85M 0.14M
Other non cash items 3.37M 1.37M 0.51M 0.47M 0.18M
Free cash flow -57.72M -32.38M -30.72M -32.45M -26.40M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TMDX
TransMedics Group Inc		 0.28
0.32%		 88.24 - 250.00 12.48 21.98 12.98 -407.23
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

200 Minuteman Road, Andover, MA, United States, 01810

978 552 0900

https://www.transmedics.com

584

Name Title Year Born
Dr. Waleed H. Hassanein M.D. Founder, Pres, MD, CEO & Director 1968
Mr. Stephen Gordon CFO. Treasurer & Sec. 1968
Dr. Tamer I. Khayal M.D. Chief Commercial Officer 1969
Ms. Miriam C. Provost Ph.D. VP of Global Regulatory Affairs NA
Ms. Laura Damme VP of Clinical Affairs NA
Mr. John F. Carey VP of Operations 1965
Mr. Mark Anderson Sr. Director of Technology Devel. NA
Ms. Susan Goodman VP of HR NA
Dr. Waleed H. Hassanein M.D. Founder, President, CEO & Director 1968
Mr. Stephen Gordon CFO, Treasurer & Secretary 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…